Previous close | 9.45 |
Open | N/A |
Bid | 0.00 |
Ask | 0.00 |
Strike | 17.50 |
Expiry date | 2025-01-17 |
Day's range | 9.45 - 9.45 |
Contract range | N/A |
Volume | |
Open interest | 3 |
CAMBRIDGE, Mass., June 24, 2024--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that the first participants were dosed in the Phase 2 EMBRAZE proof-of-concept trial, designed to assess the safety and efficacy of apitegromab, an investigational, highly selective myostatin inhib
CAMBRIDGE, Mass., June 18, 2024--Scholar Rock (NASDAQ: SRRK; the "Company"), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that the company granted inducement equity awards covering an aggregate of 96,700 shares of its common stock to 5 newly hired employees, consisting of inducement stock options to purchase
CAMBRIDGE, Mass., June 03, 2024--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced encouraging data from its Phase 1 DRAGON proof-of-concept trial of SRK-181, a selective inhibitor of latent TGFβ1 activation, in combination with pembrolizumab in patients with advanced solid tumor